Table of Contents Author Guidelines Submit a Manuscript
Journal of Skin Cancer
Volume 2018, Article ID 9602540, 13 pages
https://doi.org/10.1155/2018/9602540
Research Article

Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management

1Chris O’Brien Lifehouse, Camperdown, NSW, Australia
2Concord Repatriation General Hospital, Sydney, NSW, Australia
3Centenary Institute, Sydney, NSW, Australia
4Sydney Medical School, University of Sydney, Camperdown, NSW, Australia
5Royal Prince Alfred Hospital, Camperdown, NSW, Australia

Correspondence should be addressed to Anna J. Lomax; ua.gro.hl@xamol.anna

Received 15 August 2017; Revised 31 October 2017; Accepted 6 November 2017; Published 21 January 2018

Academic Editor: Arash Kimyai-Asadi

Copyright © 2018 Anna J. Lomax et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Ribas, “Tumor immunotherapy directed at PD-1,” The New England Journal of Medicine, vol. 366, no. 26, pp. 2517–2519, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. S. J. O'Day, O. Hamid, and W. J. Urba, “Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies,” Cancer, vol. 110, no. 12, pp. 2614–2627, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 8, pp. 711–723, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Schadendorf, F. S. Hodi, C. Robert et al., “Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma,” Journal of Clinical Oncology, vol. 33, no. 17, pp. 1889–1894, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. O. Hamid, C. Robert, A. Daud et al., “Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma,” The New England Journal of Medicine, vol. 369, no. 2, pp. 134–144, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Schachter, A. Ribas, G. V. Long, A. Arance, J-J. Grob, L. Mortier et al., Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006), The Lancet.
  7. J. D. Wolchok, V. Chiarion-Sileni, R. Gonzalez et al., “Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma,” The New England Journal of Medicine, vol. 377, no. 14, pp. 1345–1356, 2017. View at Publisher · View at Google Scholar
  8. C. Robert, A. Ribas, O. Hamid, A. Daud, J. D. Wolchok, A. M. Joshua et al., “Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001,” Journal of Clinical Oncology, vol. 34, 2016. View at Google Scholar
  9. VG. Atkinson, V. Andelkovic, and B. Gunawan, “Poster Abstracts. Pembrolizumab for Metastatic Melanoma – One Year Results of Named Patient Access Program,” Asia-Pacific Journal of Clinical Oncology, vol. 11, no. 117, 2015. View at Google Scholar
  10. T. C. Gangadhar, W. J. Hwu, M. A. Postow, O. Hamid, A. Daud, R. Dronca et al., “Society for Melanoma Research 2015 Congress. Safety and efficacy of pembrolizumab in US patients enrolled in KEYNOTE-030, an Expanded Access Program (EAP),” Pigment Cell and Melanoma Research, vol. 28, no. 6, p. 774, 2015. View at Google Scholar
  11. AM. Grimaldi, E. Simeone, L. Festino, D. Giannarelli, M. Palla et al., “Society for Melanoma Research 2015 Congress. Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients,” Pigment Cell and Melanoma Research, vol. 28, no. 6, p. 776, 2015. View at Google Scholar
  12. R. J. Motzer, B. Escudier, D. F. McDermott, S. George, H. J. Hammers, S. Srinivas et al., “Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma,” The New England Journal of Medicine, vol. 373, no. 19, 2015. View at Google Scholar
  13. H. Borghaei, L. Paz-Ares, L. Horn et al., “Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer,” The New England Journal of Medicine, vol. 373, no. 17, pp. 1627–1639, 2015. View at Publisher · View at Google Scholar
  14. P. H. O'Donnell, E. R. Plimack, J. Bellmunt et al., “Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012,” Journal of Clinical Oncology, vol. 33, pp. 296–296, 2015. View at Publisher · View at Google Scholar
  15. S. M. Ansell, A. M. Lesokhin, I. Borrello et al., “PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma,” The New England Journal of Medicine, vol. 372, no. 4, pp. 311–319, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. G. V. Long, V. Atkinson, J. S. Cebon et al., “Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial,” The Lancet Oncology, vol. 18, no. 9, pp. 1202–1210, 2017. View at Publisher · View at Google Scholar
  17. C. Robert, J. Schachter, G. V. Long et al., “Pembrolizumab versus ipilimumab in advanced melanoma,” The New England Journal of Medicine, vol. 372, no. 26, pp. 2521–2532, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. J. B. Haanen, F. Carbonnel, C. Robert et al., “Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines,” Annals of Oncology, vol. 28, 4, pp. iv119–iv142, 2017. View at Publisher · View at Google Scholar
  19. S. Bowyer, P. Prithviraj, P. Lorigan et al., “Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy,” British Journal of Cancer, vol. 114, no. 10, pp. 1084–1089, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. Management of Immune-Related Adverse Events (irAEs), Cancer Treatment Online 2017, 1993, ID: 1993 v.2.
  21. A. J. Lomax, L. Ge, S. Anand, C. Mcneil, and P. Lowe, “Bullous pemphigoid-like reaction in a patient with metastatic melanoma receiving pembrolizumab and previously treated with ipilimumab,” Australasian Journal of Dermatology, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Aperis, C. Paliouras, A. Zervos, A. Arvanitis, and P. Alivanis, “The use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients,” Journal of Renal Care, vol. 36, no. 4, pp. 180–185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Rayner, J. Baharani, S. Smith, V. Suresh, and I. Dasgupta, “Uraemic pruritus: relief of itching by gabapentin and pregabalin,” Nephron Clinical Practice, vol. 122, no. 3-4, pp. 75–79, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Larkin, V. Chiarion-Sileni, R. Gonzalez et al., “Combined nivolumab and ipilimumab or monotherapy in untreated Melanoma,” The New England Journal of Medicine, vol. 373, no. 1, pp. 23–34, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Naidoo, D. B. Page, B. T. Li et al., “Toxicities of the Anti-PD-1 and Anti-PD-L1 Immune Checkpoint Antibodies,” Annals of Oncology, vol. 26, no. 12, Article ID mdw141, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Hua, L. Boussemart, C. Mateus et al., “Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab,” JAMA Dermatology, vol. 152, no. 1, pp. 45–51, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. S. J. E. Hwang, G. Carlos, D. Wakade et al., “Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort,” Journal of the American Academy of Dermatology, vol. 74, no. 3, pp. 455–461, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. J. S. Weber, K. C. Kähler, and A. Hauschild, “Management of immune-related adverse events and kinetics of response with ipilimumab,” Journal of Clinical Oncology, vol. 30, no. 21, pp. 2691–2697, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. M. A. Postow, “Managing immune checkpoint-blocking antibody side effects,” American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting, pp. 76–83, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. L. A. Fecher, S. S. Agarwala, F. Stephen Hodi, and J. S. Weber, “Ipilimumab and its toxicities: a multidisciplinary approach,” The Oncologist, vol. 18, no. 6, pp. 733–743, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. “Yervoy (ipilimumab) immune-related adverse reaction (irAR) management guide,” 2013.
  32. A. C. Allison and E. M. Eugui, “Mycophenolate mofetil and its mechanisms of action,” International Journal of immunopharmacology, vol. 47, no. 2-3, pp. 85–118, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Cheng, A. Cooper, J. Kench et al., “Ipilimumab-induced toxicities and the gastroenterologist,” Journal of Gastroenterology and Hepatology, vol. 30, no. 4, pp. 657–666, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Tanaka, Y. Fujisawa, H. Maruyama, Y. Nakamura, K. Yoshino, M. Ohtsuka et al., “Case series of thyroid dysfunction induced by nivolumab (anti-PD-1; ONO-4538),” Annals of Oncology, vol. 26, supplement 2, pp. ii34–ii35, 2015. View at Google Scholar
  35. C. Mace, S. Diem, M. Gore, J. Larkin, and D. Morganstein, “Thyroid abnormalities during anti-PD1 cancer immunotherapy,” Endocrine Abstracts, vol. 38, p. 443, 2015. View at Publisher · View at Google Scholar
  36. L. K. Jackson, D. B. Johnson, J. A. Sosman, B. A. Murphy, and J. B. Epstein, “Oral health in oncology: impact of immunotherapy,” Supportive Care in Cancer, vol. 23, no. 1, pp. 1–3, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. M. M. K. Chan, R. F. Kefford, M. Carlino, A. Clements, and N. Manolios, “Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma,” Journal of Immunotherapy, vol. 38, no. 1, pp. 37–39, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. M. A. Postow, Managing immune checkpoint-blocking antibody side effects, American Society of Clinical Oncology Educational Book, 2015, 76–83.
  39. D. B. Johnson, J. M. Balko, M. L. Compton et al., “Fulminant myocarditis with combination immune checkpoint blockade,” The New England Journal of Medicine, vol. 375, no. 18, pp. 1749–1755, 2016. View at Publisher · View at Google Scholar · View at Scopus